glp 1 based drugs GLP-1 from the Gray Market 1 medications or looking to feel their best every day. The GLP-1 Agonists and Obesity:

Currently, there is no definitive consensus that GLP-1 receptor agonists directly cause clinically significant bone density loss independent of their weight-reducing effects

In retinal tissues from the ganglion cell layer, inner nuclear layer, and outer plexiform layer, phosphorylated AKT and ERK1/2 were considerably higher in the DR group than in the normal group

Number one is reduced appetite, and that's from the GLP-1 stimulation

Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, et al (2022) GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art

doi:10.1016/j.cgh.2023.08.034 70